Skip to content

TriangleGet started

← Full study record

NCT01871805 · OUTCOME

Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30): Phase II

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) · Source last updated 2018-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: units on a scale
Interval / dispersion: Standard Deviation
Time frame: Baseline, Weeks 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 105, 111, 117, last visit (up to 194 weeks)

What was measured

EORTC QLQ-C30 included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to lie between 0-100 scale; for each of the symptom scales, higher score=better level of functioning, lower score indicates lower level of functioning. 'Baseline' category for any parameter below (e.g. Global health status/QoL \[quality of life\]) represents absolute data at baseline. QoL=quality of life

Analysis population: Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure. 'Number Analyzed' = number of participants evaluable at the specified timepoint.

Groups in this outcome

Alectinib 600 mg (Fed): Phase II

Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Reported measurements

Global health status/QoL: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	53.59	24.27	Not reported	Not reported	Not reported

Global health status/QoL: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	15.89	25.66	Not reported	Not reported	Not reported

Global health status/QoL: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Global health status/QoL: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	18.83	23.41	Not reported	Not reported	Not reported

Global health status/QoL: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Global health status/QoL: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	15.65	23.73	Not reported	Not reported	Not reported

Global health status/QoL: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Global health status/QoL: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	41

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	15.65	20.77	Not reported	Not reported	Not reported

Global health status/QoL: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Global health status/QoL: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	13.03	19.57	Not reported	Not reported	Not reported

Global health status/QoL: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	9.62	Not reported	Not reported	Not reported

Global health status/QoL: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.28	20.57	Not reported	Not reported	Not reported

Global health status/QoL: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	5.89	Not reported	Not reported	Not reported

Global health status/QoL: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	10.19	19.33	Not reported	Not reported	Not reported

Global health status/QoL: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-10.42	12.50	Not reported	Not reported	Not reported

Global health status/QoL: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.06	Not reported	Not reported	Not reported

Global health status/QoL: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.50	17.68	Not reported	Not reported	Not reported

Global health status/QoL: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.95	16.86	Not reported	Not reported	Not reported

Global health status/QoL: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.33	21.73	Not reported	Not reported	Not reported

Global health status/QoL: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	10.28	19.54	Not reported	Not reported	Not reported

Global health status/QoL: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Global health status/QoL: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	15.06	17.80	Not reported	Not reported	Not reported

Global health status/QoL: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.50	15.96	Not reported	Not reported	Not reported

Global health status/QoL: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	18.12	Not reported	Not reported	Not reported

Global health status/QoL: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Global health status/QoL: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	10.32	16.44	Not reported	Not reported	Not reported

Global health status/QoL: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Global health status/QoL: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	10.90	14.98	Not reported	Not reported	Not reported

Global health status/QoL: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Global health status/QoL: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	11.79	Not reported	Not reported	Not reported

Global health status/QoL: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-29.17	41.25	Not reported	Not reported	Not reported

Global health status/QoL: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	22.05	Not reported	Not reported	Not reported

Global health status/QoL: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	Not reported	Not reported	Not reported	Not reported

Global health status/QoL: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	Not reported	Not reported	Not reported	Not reported

Global health status/QoL: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Global health status/QoL: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Global health status/QoL: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.99	21.27	Not reported	Not reported	Not reported

Physical functioning: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	69.96	24.43	Not reported	Not reported	Not reported

Physical functioning: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.69	17.44	Not reported	Not reported	Not reported

Physical functioning: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Physical functioning: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.20	22.37	Not reported	Not reported	Not reported

Physical functioning: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Physical functioning: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	51

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.58	18.23	Not reported	Not reported	Not reported

Physical functioning: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Physical functioning: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	42

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.13	16.33	Not reported	Not reported	Not reported

Physical functioning: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	3.33	4.71	Not reported	Not reported	Not reported

Physical functioning: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.22	17.39	Not reported	Not reported	Not reported

Physical functioning: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	13.33	Not reported	Not reported	Not reported

Physical functioning: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.21	18.10	Not reported	Not reported	Not reported

Physical functioning: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	3.33	14.14	Not reported	Not reported	Not reported

Physical functioning: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.85	18.89	Not reported	Not reported	Not reported

Physical functioning: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.33	22.11	Not reported	Not reported	Not reported

Physical functioning: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.25	16.81	Not reported	Not reported	Not reported

Physical functioning: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	18.86	Not reported	Not reported	Not reported

Physical functioning: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.67	18.32	Not reported	Not reported	Not reported

Physical functioning: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	20.55	Not reported	Not reported	Not reported

Physical functioning: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.56	22.67	Not reported	Not reported	Not reported

Physical functioning: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.67	11.55	Not reported	Not reported	Not reported

Physical functioning: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.97	19.13	Not reported	Not reported	Not reported

Physical functioning: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	16.67	Not reported	Not reported	Not reported

Physical functioning: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.20	22.70	Not reported	Not reported	Not reported

Physical functioning: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Physical functioning: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.98	19.83	Not reported	Not reported	Not reported

Physical functioning: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Physical functioning: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	3.08	21.71	Not reported	Not reported	Not reported

Physical functioning: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.67	11.55	Not reported	Not reported	Not reported

Physical functioning: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.50	18.32	Not reported	Not reported	Not reported

Physical functioning: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-26.67	28.28	Not reported	Not reported	Not reported

Physical functioning: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	11.55	Not reported	Not reported	Not reported

Physical functioning: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.67	Not reported	Not reported	Not reported	Not reported

Physical functioning: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Physical functioning: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Physical functioning: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Physical functioning: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.28	21.64	Not reported	Not reported	Not reported

Role functioning: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	58.86	34.06	Not reported	Not reported	Not reported

Role functioning: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	14.84	32.00	Not reported	Not reported	Not reported

Role functioning: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Role functioning: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.65	32.69	Not reported	Not reported	Not reported

Role functioning: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Role functioning: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	51

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.42	31.94	Not reported	Not reported	Not reported

Role functioning: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Role functioning: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	42

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.73	27.85	Not reported	Not reported	Not reported

Role functioning: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	11.79	Not reported	Not reported	Not reported

Role functioning: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.83	24.70	Not reported	Not reported	Not reported

Role functioning: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-33.33	33.33	Not reported	Not reported	Not reported

Role functioning: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.65	24.70	Not reported	Not reported	Not reported

Role functioning: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-33.33	0.00	Not reported	Not reported	Not reported

Role functioning: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.48	28.81	Not reported	Not reported	Not reported

Role functioning Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-20.83	15.96	Not reported	Not reported	Not reported

Role functioning: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	10.94	24.54	Not reported	Not reported	Not reported

Role functioning: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Role functioning: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.29	24.30	Not reported	Not reported	Not reported

Role functioning: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-13.33	18.26	Not reported	Not reported	Not reported

Role functioning: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.89	27.24	Not reported	Not reported	Not reported

Role functioning: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	9.62	Not reported	Not reported	Not reported

Role functioning: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.97	29.90	Not reported	Not reported	Not reported

Role functioning: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	33.33	Not reported	Not reported	Not reported

Role functioning: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.97	27.46	Not reported	Not reported	Not reported

Role functioning: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Role functioning: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.52	28.66	Not reported	Not reported	Not reported

Role functioning: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Role functioning: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.13	31.46	Not reported	Not reported	Not reported

Role functioning: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	19.25	Not reported	Not reported	Not reported

Role functioning: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.17	19.42	Not reported	Not reported	Not reported

Role functioning: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-41.67	35.36	Not reported	Not reported	Not reported

Role functioning: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Role functioning: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	Not reported	Not reported	Not reported	Not reported

Role functioning: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Role functioning: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Role functioning: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Role functioning: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.36	34.47	Not reported	Not reported	Not reported

Emotional functioning: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	73.49	21.40	Not reported	Not reported	Not reported

Emotional functioning: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.99	18.75	Not reported	Not reported	Not reported

Emotional functioning: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Emotional functioning: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.01	17.04	Not reported	Not reported	Not reported

Emotional functioning: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Emotional functioning: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	13.44	21.17	Not reported	Not reported	Not reported

Emotional functioning: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Emotional functioning: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	41

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	10.37	16.75	Not reported	Not reported	Not reported

Emotional functioning: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.17	5.89	Not reported	Not reported	Not reported

Emotional functioning: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.40	20.34	Not reported	Not reported	Not reported

Emotional functioning: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-30.56	26.79	Not reported	Not reported	Not reported

Emotional functioning: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.89	19.85	Not reported	Not reported	Not reported

Emotional functioning: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.17	5.89	Not reported	Not reported	Not reported

Emotional functioning: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.41	18.12	Not reported	Not reported	Not reported

Emotional functioning Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.25	7.98	Not reported	Not reported	Not reported

Emotional functioning: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.73	15.23	Not reported	Not reported	Not reported

Emotional functioning: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Emotional functioning: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	3.49	13.40	Not reported	Not reported	Not reported

Emotional functioning: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.67	18.07	Not reported	Not reported	Not reported

Emotional functioning: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	3.33	14.12	Not reported	Not reported	Not reported

Emotional functioning: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	34.69	Not reported	Not reported	Not reported

Emotional functioning: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.45	14.52	Not reported	Not reported	Not reported

Emotional functioning: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	26.35	Not reported	Not reported	Not reported

Emotional functioning: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.07	21.43	Not reported	Not reported	Not reported

Emotional functioning: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	11.79	Not reported	Not reported	Not reported

Emotional functioning: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.19	19.77	Not reported	Not reported	Not reported

Emotional functioning: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	5.89	Not reported	Not reported	Not reported

Emotional functioning: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.28	19.79	Not reported	Not reported	Not reported

Emotional functioning: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	34.69	Not reported	Not reported	Not reported

Emotional functioning: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.04	8.26	Not reported	Not reported	Not reported

Emotional functioning: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.50	17.68	Not reported	Not reported	Not reported

Emotional functioning: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Emotional functioning: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Emotional functioning: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Emotional functioning: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Emotional functioning: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Emotional functioning: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.76	19.86	Not reported	Not reported	Not reported

Cognitive functioning: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	77.85	24.13	Not reported	Not reported	Not reported

Cognitive functioning: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.34	20.76	Not reported	Not reported	Not reported

Cognitive functioning: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Cognitive functioning: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.78	15.44	Not reported	Not reported	Not reported

Cognitive functioning: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Cognitive functioning: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.04	15.82	Not reported	Not reported	Not reported

Cognitive functioning: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Cognitive functioning: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	41

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.25	16.34	Not reported	Not reported	Not reported

Cognitive functioning: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Cognitive functioning: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.28	17.68	Not reported	Not reported	Not reported

Cognitive functioning: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-27.78	25.46	Not reported	Not reported	Not reported

Cognitive functioning: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.63	13.16	Not reported	Not reported	Not reported

Cognitive functioning: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-25.00	35.36	Not reported	Not reported	Not reported

Cognitive functioning: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.46	14.08	Not reported	Not reported	Not reported

Cognitive functioning Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.17	51.59	Not reported	Not reported	Not reported

Cognitive functioning: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.06	21.58	Not reported	Not reported	Not reported

Cognitive functioning: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-33.33	0.00	Not reported	Not reported	Not reported

Cognitive functioning: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.53	22.29	Not reported	Not reported	Not reported

Cognitive functioning: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	31.18	Not reported	Not reported	Not reported

Cognitive functioning: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.11	21.66	Not reported	Not reported	Not reported

Cognitive functioning: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Cognitive functioning: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.97	22.23	Not reported	Not reported	Not reported

Cognitive functioning: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	8.33	Not reported	Not reported	Not reported

Cognitive functioning: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.97	20.64	Not reported	Not reported	Not reported

Cognitive functioning: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Cognitive functioning: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.52	25.59	Not reported	Not reported	Not reported

Cognitive functioning: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Cognitive functioning: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.85	20.59	Not reported	Not reported	Not reported

Cognitive functioning: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	19.25	Not reported	Not reported	Not reported

Cognitive functioning: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	15.43	Not reported	Not reported	Not reported

Cognitive functioning: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Cognitive functioning: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-22.22	19.25	Not reported	Not reported	Not reported

Cognitive functioning: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Cognitive functioning: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Cognitive functioning: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Cognitive functioning: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Cognitive functioning: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.79	24.45	Not reported	Not reported	Not reported

Social functioning: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	60.55	35.32	Not reported	Not reported	Not reported

Social functioning: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.20	23.20	Not reported	Not reported	Not reported

Social functioning: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Social functioning: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	10.19	27.93	Not reported	Not reported	Not reported

Social functioning: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Social functioning: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	13.27	25.45	Not reported	Not reported	Not reported

Social functioning: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Social functioning: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	41

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.54	26.38	Not reported	Not reported	Not reported

Social functioning: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Social functioning: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	14.53	31.11	Not reported	Not reported	Not reported

Social functioning: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.56	25.46	Not reported	Not reported	Not reported

Social functioning: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.21	32.35	Not reported	Not reported	Not reported

Social functioning: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	11.79	Not reported	Not reported	Not reported

Social functioning: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.80	30.47	Not reported	Not reported	Not reported

Social functioning: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	20.97	Not reported	Not reported	Not reported

Social functioning: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.16	29.31	Not reported	Not reported	Not reported

Social functioning: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	11.79	Not reported	Not reported	Not reported

Social functioning: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.37	28.53	Not reported	Not reported	Not reported

Social functioning: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	3.33	18.26	Not reported	Not reported	Not reported

Social functioning: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	25.43	Not reported	Not reported	Not reported

Social functioning: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	33.33	Not reported	Not reported	Not reported

Social functioning: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.77	31.95	Not reported	Not reported	Not reported

Social functioning: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	20.83	25.00	Not reported	Not reported	Not reported

Social functioning: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.59	23.80	Not reported	Not reported	Not reported

Social functioning: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Social functioning: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.70	23.51	Not reported	Not reported	Not reported

Social functioning: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Social functioning: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.97	29.36	Not reported	Not reported	Not reported

Social functioning: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	27.78	25.46	Not reported	Not reported	Not reported

Social functioning: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	14.58	16.52	Not reported	Not reported	Not reported

Social functioning: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	82.50	Not reported	Not reported	Not reported

Social functioning: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	16.67	Not reported	Not reported	Not reported

Social functioning: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Social functioning: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Social functioning: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Social functioning: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Social functioning: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	3.20	30.39	Not reported	Not reported	Not reported

Fatigue: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	45.57	27.02	Not reported	Not reported	Not reported

Fatigue: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-10.94	25.70	Not reported	Not reported	Not reported

Fatigue: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	Not reported	Not reported	Not reported	Not reported

Fatigue: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	27.73	Not reported	Not reported	Not reported

Fatigue: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Fatigue: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	51

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.85	24.88	Not reported	Not reported	Not reported

Fatigue: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Fatigue: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	42

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-10.05	22.06	Not reported	Not reported	Not reported

Fatigue: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.56	7.86	Not reported	Not reported	Not reported

Fatigue: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.97	23.47	Not reported	Not reported	Not reported

Fatigue: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	14.81	6.42	Not reported	Not reported	Not reported

Fatigue: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-10.23	25.75	Not reported	Not reported	Not reported

Fatigue: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.56	7.86	Not reported	Not reported	Not reported

Fatigue: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.26	21.50	Not reported	Not reported	Not reported

Fatigue: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	24.00	Not reported	Not reported	Not reported

Fatigue: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	22.93	Not reported	Not reported	Not reported

Fatigue: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	47.14	Not reported	Not reported	Not reported

Fatigue: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.64	18.39	Not reported	Not reported	Not reported

Fatigue: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.44	16.85	Not reported	Not reported	Not reported

Fatigue: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.78	21.27	Not reported	Not reported	Not reported

Fatigue: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.41	23.13	Not reported	Not reported	Not reported

Fatigue: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.69	20.07	Not reported	Not reported	Not reported

Fatigue: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	10.64	Not reported	Not reported	Not reported

Fatigue: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.21	22.28	Not reported	Not reported	Not reported

Fatigue: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	7.86	Not reported	Not reported	Not reported

Fatigue: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.35	23.19	Not reported	Not reported	Not reported

Fatigue: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	7.86	Not reported	Not reported	Not reported

Fatigue: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.40	18.62	Not reported	Not reported	Not reported

Fatigue: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	11.11	Not reported	Not reported	Not reported

Fatigue: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	17.57	Not reported	Not reported	Not reported

Fatigue: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	31.43	Not reported	Not reported	Not reported

Fatigue: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-18.52	6.42	Not reported	Not reported	Not reported

Fatigue: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Fatigue: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Fatigue: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Fatigue: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Fatigue: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.85	21.65	Not reported	Not reported	Not reported

Nausea and vomiting: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	15.61	20.73	Not reported	Not reported	Not reported

Nausea and vomiting: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.77	19.63	Not reported	Not reported	Not reported

Nausea and vomiting: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Nausea and vomiting: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.02	21.66	Not reported	Not reported	Not reported

Nausea and vomiting: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Nausea and vomiting: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	51

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.15	19.81	Not reported	Not reported	Not reported

Nausea and vomiting: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Nausea and vomiting: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	42

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.13	18.48	Not reported	Not reported	Not reported

Nausea and vomiting: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	11.79	Not reported	Not reported	Not reported

Nausea and vomiting: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.98	17.31	Not reported	Not reported	Not reported

Nausea and vomiting: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	25.46	Not reported	Not reported	Not reported

Nausea and vomiting: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.46	17.63	Not reported	Not reported	Not reported

Nausea and vomiting: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Nausea and vomiting: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.80	18.47	Not reported	Not reported	Not reported

Nausea and vomiting: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.17	8.33	Not reported	Not reported	Not reported

Nausea and vomiting: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.38	19.37	Not reported	Not reported	Not reported

Nausea and vomiting: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	11.79	Not reported	Not reported	Not reported

Nausea and vomiting: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.85	19.85	Not reported	Not reported	Not reported

Nausea and vomiting: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.67	14.91	Not reported	Not reported	Not reported

Nausea and vomiting: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.67	17.29	Not reported	Not reported	Not reported

Nausea and vomiting: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Nausea and vomiting: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.05	20.10	Not reported	Not reported	Not reported

Nausea and vomiting: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Nausea and vomiting: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.80	19.85	Not reported	Not reported	Not reported

Nausea and vomiting: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Nausea and vomiting: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	13.26	Not reported	Not reported	Not reported

Nausea and vomiting: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Nausea and vomiting: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.41	12.80	Not reported	Not reported	Not reported

Nausea and vomiting: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.56	9.62	Not reported	Not reported	Not reported

Nausea and vomiting: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.08	13.91	Not reported	Not reported	Not reported

Nausea and vomiting: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Nausea and vomiting: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	16.67	Not reported	Not reported	Not reported

Nausea and vomiting: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Nausea and vomiting: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Nausea and vomiting: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Nausea and vomiting: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Nausea and vomiting: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.85	20.38	Not reported	Not reported	Not reported

Pain: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	36.29	33.63	Not reported	Not reported	Not reported

Pain: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.50	33.47	Not reported	Not reported	Not reported

Pain: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-14.81	32.48	Not reported	Not reported	Not reported

Pain: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	51

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-13.07	33.55	Not reported	Not reported	Not reported

Pain: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	42

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.35	31.44	Not reported	Not reported	Not reported

Pain: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	11.79	Not reported	Not reported	Not reported

Pain: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.13	33.37	Not reported	Not reported	Not reported

Pain: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.56	9.62	Not reported	Not reported	Not reported

Pain: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.14	34.31	Not reported	Not reported	Not reported

Pain: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	11.79	Not reported	Not reported	Not reported

Pain: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.09	23.17	Not reported	Not reported	Not reported

Pain: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	21.52	Not reported	Not reported	Not reported

Pain: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.55	17.81	Not reported	Not reported	Not reported

Pain: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-25.00	11.79	Not reported	Not reported	Not reported

Pain: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-0.52	24.86	Not reported	Not reported	Not reported

Pain: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	39.09	Not reported	Not reported	Not reported

Pain: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.56	14.17	Not reported	Not reported	Not reported

Pain: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	9.62	Not reported	Not reported	Not reported

Pain: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.13	23.46	Not reported	Not reported	Not reported

Pain: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.17	15.96	Not reported	Not reported	Not reported

Pain: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.07	28.62	Not reported	Not reported	Not reported

Pain: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	11.79	Not reported	Not reported	Not reported

Pain: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.59	15.73	Not reported	Not reported	Not reported

Pain: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	11.79	Not reported	Not reported	Not reported

Pain: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.13	19.70	Not reported	Not reported	Not reported

Pain: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	9.62	Not reported	Not reported	Not reported

Pain: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	25.20	Not reported	Not reported	Not reported

Pain: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	25.00	35.36	Not reported	Not reported	Not reported

Pain: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	53.58	Not reported	Not reported	Not reported

Pain: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Pain: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.36	29.92	Not reported	Not reported	Not reported

Dyspnoea: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	78

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	30.86	Not reported	Not reported	Not reported

Dyspnoea: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	63

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.17	32.96	Not reported	Not reported	Not reported

Dyspnoea : Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	53

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-10.69	32.54	Not reported	Not reported	Not reported

Dyspnoea: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	50

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-12.67	30.78	Not reported	Not reported	Not reported

Dyspnoea: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	40

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.50	25.58	Not reported	Not reported	Not reported

Dyspnoea: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Dyspnoea: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.89	26.21	Not reported	Not reported	Not reported

Dyspnoea: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	33.33	Not reported	Not reported	Not reported

Dyspnoea: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	37

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.21	27.37	Not reported	Not reported	Not reported

Dyspnoea: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Dyspnoea: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	35

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.71	27.40	Not reported	Not reported	Not reported

Dyspnoea: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	27.22	Not reported	Not reported	Not reported

Dyspnoea: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.25	28.63	Not reported	Not reported	Not reported

Dyspnoea: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Dyspnoea: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.29	23.55	Not reported	Not reported	Not reported

Dyspnoea: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.67	14.91	Not reported	Not reported	Not reported

Dyspnoea: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.11	22.29	Not reported	Not reported	Not reported

Dyspnoea: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	19.25	Not reported	Not reported	Not reported

Dyspnoea: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.97	24.14	Not reported	Not reported	Not reported

Dyspnoea: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	16.67	Not reported	Not reported	Not reported

Dyspnoea: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.45	32.53	Not reported	Not reported	Not reported

Dyspnoea: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Dyspnoea: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.76	21.82	Not reported	Not reported	Not reported

Dyspnoea: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Dyspnoea: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	23.57	Not reported	Not reported	Not reported

Dyspnoea: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	19.25	Not reported	Not reported	Not reported

Dyspnoea: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	29.55	Not reported	Not reported	Not reported

Dyspnoea: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Dyspnoea: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	38.49	Not reported	Not reported	Not reported

Dyspnoea: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Dyspnoea: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	72

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.63	33.71	Not reported	Not reported	Not reported

Insomnia: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	31.22	30.82	Not reported	Not reported	Not reported

Insomnia: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.38	29.38	Not reported	Not reported	Not reported

Insomnia: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Insomnia: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.26	34.52	Not reported	Not reported	Not reported

Insomnia: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Insomnia: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	51

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.27	37.86	Not reported	Not reported	Not reported

Insomnia: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Insomnia: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	42

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.17	36.67	Not reported	Not reported	Not reported

Insomnia: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Insomnia: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-9.40	33.29	Not reported	Not reported	Not reported

Insomnia: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	44.44	50.92	Not reported	Not reported	Not reported

Insomnia: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.77	40.03	Not reported	Not reported	Not reported

Insomnia: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	83.33	23.57	Not reported	Not reported	Not reported

Insomnia: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	25.82	Not reported	Not reported	Not reported

Insomnia: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	41.67	31.91	Not reported	Not reported	Not reported

Insomnia: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.13	29.77	Not reported	Not reported	Not reported

Insomnia: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	50.00	23.57	Not reported	Not reported	Not reported

Insomnia: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.08	28.00	Not reported	Not reported	Not reported

Insomnia: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	40.00	43.46	Not reported	Not reported	Not reported

Insomnia: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.11	28.34	Not reported	Not reported	Not reported

Insomnia: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	33.33	Not reported	Not reported	Not reported

Insomnia: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	25

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.33	32.89	Not reported	Not reported	Not reported

Insomnia: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	27.22	Not reported	Not reported	Not reported

Insomnia: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	26.59	Not reported	Not reported	Not reported

Insomnia: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Insomnia: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.59	22.30	Not reported	Not reported	Not reported

Insomnia: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Insomnia: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	36.00	Not reported	Not reported	Not reported

Insomnia: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Insomnia: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	30.86	Not reported	Not reported	Not reported

Insomnia: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Insomnia: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	22.22	38.49	Not reported	Not reported	Not reported

Insomnia: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Insomnia: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Insomnia: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Insomnia: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Insomnia: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.83	35.09	Not reported	Not reported	Not reported

Appetite loss: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	29.96	33.16	Not reported	Not reported	Not reported

Appetite loss: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	30.28	Not reported	Not reported	Not reported

Appetite loss: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Appetite loss: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-18.52	36.44	Not reported	Not reported	Not reported

Appetite loss: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Appetite loss: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	51

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-20.26	33.39	Not reported	Not reported	Not reported

Appetite loss: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Appetite loss: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	42

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-19.84	29.50	Not reported	Not reported	Not reported

Appetite loss: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Appetite loss: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-13.68	23.84	Not reported	Not reported	Not reported

Appetite loss: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-44.44	19.25	Not reported	Not reported	Not reported

Appetite loss: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-14.91	27.62	Not reported	Not reported	Not reported

Appetite loss: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-50.00	23.57	Not reported	Not reported	Not reported

Appetite loss: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	32.37	Not reported	Not reported	Not reported

Appetite loss: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	41.94	Not reported	Not reported	Not reported

Appetite loss: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-20.83	34.65	Not reported	Not reported	Not reported

Appetite loss: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-33.33	47.14	Not reported	Not reported	Not reported

Appetite loss: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-18.75	32.72	Not reported	Not reported	Not reported

Appetite loss: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-20.00	29.81	Not reported	Not reported	Not reported

Appetite loss: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-20.00	31.07	Not reported	Not reported	Not reported

Appetite loss: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Appetite loss: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-23.08	33.69	Not reported	Not reported	Not reported

Appetite loss: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	33.33	Not reported	Not reported	Not reported

Appetite loss: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-23.19	30.87	Not reported	Not reported	Not reported

Appetite loss: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Appetite loss: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-20.63	30.69	Not reported	Not reported	Not reported

Appetite loss: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Appetite loss: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-25.64	36.40	Not reported	Not reported	Not reported

Appetite loss: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Appetite loss: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-20.83	39.59	Not reported	Not reported	Not reported

Appetite loss: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Appetite loss: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-55.56	50.92	Not reported	Not reported	Not reported

Appetite loss: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Appetite loss: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Appetite loss: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Appetite loss: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Appetite loss: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-13.70	33.72	Not reported	Not reported	Not reported

Constipation: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	20.25	26.38	Not reported	Not reported	Not reported

Constipation: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.90	30.68	Not reported	Not reported	Not reported

Constipation: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Constipation: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.85	31.33	Not reported	Not reported	Not reported

Constipation: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	Not reported	Not reported	Not reported	Not reported

Constipation: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	51

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.58	25.84	Not reported	Not reported	Not reported

Constipation: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Constipation: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	42

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.38	29.81	Not reported	Not reported	Not reported

Constipation: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	47.14	Not reported	Not reported	Not reported

Constipation: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.13	27.08	Not reported	Not reported	Not reported

Constipation: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	50.92	Not reported	Not reported	Not reported

Constipation: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.26	21.26	Not reported	Not reported	Not reported

Constipation: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Constipation: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.26	24.70	Not reported	Not reported	Not reported

Constipation: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	50.00	19.25	Not reported	Not reported	Not reported

Constipation: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.04	26.07	Not reported	Not reported	Not reported

Constipation: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Constipation: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.45	23.44	Not reported	Not reported	Not reported

Constipation: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	26.67	43.46	Not reported	Not reported	Not reported

Constipation: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.67	22.15	Not reported	Not reported	Not reported

Constipation: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	44.44	38.49	Not reported	Not reported	Not reported

Constipation: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.82	26.79	Not reported	Not reported	Not reported

Constipation: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	16.67	Not reported	Not reported	Not reported

Constipation: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	4.35	25.23	Not reported	Not reported	Not reported

Constipation: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	47.14	Not reported	Not reported	Not reported

Constipation: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.94	17.97	Not reported	Not reported	Not reported

Constipation: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	47.14	Not reported	Not reported	Not reported

Constipation: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	7.69	19.97	Not reported	Not reported	Not reported

Constipation: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	22.22	38.49	Not reported	Not reported	Not reported

Constipation: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	15.43	Not reported	Not reported	Not reported

Constipation: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	47.14	Not reported	Not reported	Not reported

Constipation: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-11.11	50.92	Not reported	Not reported	Not reported

Constipation: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	Not reported	Not reported	Not reported	Not reported

Constipation: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Constipation: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Constipation: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Constipation: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.68	31.93	Not reported	Not reported	Not reported

Diarrhoea: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	78

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	13.25	23.01	Not reported	Not reported	Not reported

Diarrhoea: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	63

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.41	25.00	Not reported	Not reported	Not reported

Diarrhoea: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Diarrhoea: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	53

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.29	23.62	Not reported	Not reported	Not reported

Diarrhoea: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Diarrhoea: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	48

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-5.56	25.11	Not reported	Not reported	Not reported

Diarrhoea: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Diarrhoea: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	40

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.17	28.43	Not reported	Not reported	Not reported

Diarrhoea: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Diarrhoea: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.55	23.84	Not reported	Not reported	Not reported

Diarrhoea: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Diarrhoea: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.89	23.80	Not reported	Not reported	Not reported

Diarrhoea: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Diarrhoea: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.48	26.21	Not reported	Not reported	Not reported

Diarrhoea: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Diarrhoea: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.03	28.09	Not reported	Not reported	Not reported

Diarrhoea: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Diarrhoea: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	32

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.25	26.01	Not reported	Not reported	Not reported

Diarrhoea: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Diarrhoea: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-1.11	32.14	Not reported	Not reported	Not reported

Diarrhoea: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Diarrhoea: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.69	30.27	Not reported	Not reported	Not reported

Diarrhoea: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Diarrhoea: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-7.25	28.35	Not reported	Not reported	Not reported

Diarrhoea: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Diarrhoea: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	20

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.67	25.59	Not reported	Not reported	Not reported

Diarrhoea: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Diarrhoea: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	12

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	2.78	26.43	Not reported	Not reported	Not reported

Diarrhoea: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Diarrhoea: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	7

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	9.52	16.27	Not reported	Not reported	Not reported

Diarrhoea: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Diarrhoea: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	33.33	47.14	Not reported	Not reported	Not reported

Diarrhoea: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Diarrhoea: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Diarrhoea: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Diarrhoea: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Diarrhoea: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	72

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.31	28.15	Not reported	Not reported	Not reported

Financial difficulties: Baseline

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	79

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	30.80	33.24	Not reported	Not reported	Not reported

Financial difficulties: Week 6

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	64

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.60	21.66	Not reported	Not reported	Not reported

Financial difficulties: Week 9

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Financial difficulties: Week 12

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	54

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.32	23.39	Not reported	Not reported	Not reported

Financial difficulties: Week 15

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Financial difficulties: Week 18

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	49

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.76	21.52	Not reported	Not reported	Not reported

Financial difficulties: Week 21

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Financial difficulties: Week 24

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	41

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.44	26.24	Not reported	Not reported	Not reported

Financial difficulties: Week 27

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Financial difficulties: Week 30

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	39

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.84	23.17	Not reported	Not reported	Not reported

Financial difficulties: Week 33

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	11.11	19.25	Not reported	Not reported	Not reported

Financial difficulties: Week 36

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	38

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.14	27.79	Not reported	Not reported	Not reported

Financial difficulties: Week 39

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Financial difficulties: Week 42

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	36

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-6.48	20.81	Not reported	Not reported	Not reported

Financial difficulties: Week 45

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	8.33	16.67	Not reported	Not reported	Not reported

Financial difficulties: Week 48

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	33

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.08	23.61	Not reported	Not reported	Not reported

Financial difficulties: Week 51

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	16.67	23.57	Not reported	Not reported	Not reported

Financial difficulties: Week 54

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	31

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.15	27.13	Not reported	Not reported	Not reported

Financial difficulties: Week 57

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	5

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	6.67	14.91	Not reported	Not reported	Not reported

Financial difficulties: Week 60

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	30

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-3.33	22.06	Not reported	Not reported	Not reported

Financial difficulties: Week 63

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Financial difficulties: Week 66

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	26

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-2.56	28.16	Not reported	Not reported	Not reported

Financial difficulties: Week 69

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	4

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-8.33	16.67	Not reported	Not reported	Not reported

Financial difficulties: Week 72

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	23

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	5.80	25.92	Not reported	Not reported	Not reported

Financial difficulties: Week 75

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Financial difficulties: Week 78

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	21

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	34.96	Not reported	Not reported	Not reported

Financial difficulties: Week 81

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Financial difficulties: Week 84

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	13

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	12.82	34.80	Not reported	Not reported	Not reported

Financial difficulties: Week 87

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	0.00	Not reported	Not reported	Not reported

Financial difficulties: Week 90

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	8

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-4.17	21.36	Not reported	Not reported	Not reported

Financial difficulties: Week 93

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	2

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	-16.67	23.57	Not reported	Not reported	Not reported

Financial difficulties: Week 96

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	3

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	22.22	38.49	Not reported	Not reported	Not reported

Financial difficulties: Week 99

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Financial difficulties: Week 105

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Financial difficulties: Week 111

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Financial difficulties: Week 117

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	1

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	0.00	Not reported	Not reported	Not reported	Not reported

Financial difficulties: Last visit

Analysis denominator · Participants

Group	Source count
Alectinib 600 mg (Fed): Phase II	73

Values in units on a scale · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Alectinib 600 mg (Fed): Phase II	1.83	32.82	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
24.27
value
53.59
denoms
counts
group Id
OG000
value
79
units
Participants
title
Global health status/QoL: Baseline
categories
measurements
group Id
OG000
spread
25.66
value
15.89
denoms
counts
group Id
OG000
value
64
units
Participants
title
Global health status/QoL: Week 6
categories
measurements
group Id
OG000
value
0.00
denoms
counts
group Id
OG000
value
1
units
Participants
title
Global health status/QoL: Week 9
categories
measurements
group Id
OG000
spread
23.41
value
18.83
denoms
counts
group Id
OG000
value
54
units
Participants
title
Global health status/QoL: Week 12
categories
measurements
group Id
OG000
value
0.00
denoms
counts
group Id
OG000
value
1
units
Participants
title
Global health status/QoL: Week 15
categories
measurements
group Id
OG000
spread
23.73
value
15.65
denoms
counts
group Id
OG000
value
49
units
Participants
title
Global health status/QoL: Week 18
categories
measurements
group Id
OG000
value
0.00
denoms
counts
group Id
OG000
value
1
units
Participants
title
Global health status/QoL: Week 21
categories
measurements
group Id
OG000
spread
20.77
value
15.65
denoms
counts
group Id
OG000
value
41
units
Participants
title
Global health status/QoL: Week 24
categories
measurements
group Id
OG000
spread
0.00
value
0.00
denoms
counts
group Id
OG000
value
2
units
Participants
title
Global health status/QoL: Week 27
categories
measurements
group Id
OG000
spread
19.57
value
13.03
denoms
counts
group Id
OG000
value
39
units
Participants
title
Global health status/QoL: Week 30
categories
measurements
group Id
OG000
spread
9.62
value
-5.56
denoms
counts
group Id
OG000
value
3
units
Participants
title
Global health status/QoL: Week 33
categories
measurements
group Id
OG000
spread
20.57
value
12.28
denoms
counts
group Id
OG000
value
38
units
Participants
title
Global health status/QoL: Week 36

denoms

counts
group Id
OG000
value
79
units
Participants

description

EORTC QLQ-C30 included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to lie between 0-100 scale; for each of the symptom scales, higher score=better level of functioning, lower score indicates lower level of functioning. 'Baseline' category for any parameter below (e.g. Global health status/QoL \[quality of life\]) represents absolute data at baseline. QoL=quality of life

dispersion Type

Standard Deviation

groups

description
Participants received 600 mg alectinib capsules orally BID from Cycle 1 Day 1 for 3-weekly cycles until disease progression, death or withdrawal for any other reasons.
id
OG000
title
Alectinib 600 mg (Fed): Phase II

param Type

MEAN

population Description

Phase II safety population. 'Overall Number of Participants Analyzed' = participants evaluable for this outcome measure. 'Number Analyzed' = number of participants evaluable at the specified timepoint.

reporting Status

POSTED

time Frame

Baseline, Weeks 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 105, 111, 117, last visit (up to 194 weeks)

title

Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30): Phase II

type

SECONDARY

unit Of Measure

units on a scale

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice